
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember, there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Remember that no prescription is required. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch …
Express Scripts (ESRX), one of the largest U.S. prescription benefit managers, will cover new migraine drugs from Eli Lilly (LLY) and Amgen (AMGN), but is excluding a rival medication made by Teva Pharmaceutical (TEVA) after price negotiations with all three manufacturers, Reuters reports. The decision represents a setback for Teva, which is in the midst of a corporate restructuring and hoped to capture a sizable stake of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use to the patients it says are most likely to benefit from the new Amgen and Lilly migraine drugs.